Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B

[1]  A. E. Yeo,et al.  Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection , 2004, Journal of Gastroenterology.

[2]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[3]  C. Gibbs,et al.  Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil , 2003 .

[4]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[5]  H. Lei,et al.  Prevalence and significance of hepatitis B virus (HBV) pre‐S mutants in serum and liver at different replicative stages of chronic HBV infection , 2001, Hepatology.

[6]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[7]  O. Yokosuka,et al.  Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients , 2000, Journal of medical virology.

[8]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[9]  R. D. de Man,et al.  Lamivudine resistance inimmunocompetent chronic hepatitis B , 1997 .

[10]  T. Okanoue,et al.  Significance of pre‐S region–defective hepatitis B virus that emerged during exacerbation of chronic type B hepatitis , 1993, Hepatology.

[11]  B. Moss,et al.  Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens , 1992, Journal of virology.

[12]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[13]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[14]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .

[15]  R. D. de Man,et al.  Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. , 1997, Journal of hepatology.

[16]  O. Yokosuka,et al.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. , 1992, The Journal of clinical investigation.